$1995 | Single User
$2995 | Multi User
$5995 | Site License
$9995 | Global License

Global Joint Venture Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2010-2017 [Report Updated: 01-09-2017]

Published by Current Partnering: 01 Sep 2017 | 117451 | In Stock

Introduction

The Global Joint Venture Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2010-2017 report provides comprehensive understanding and unprecedented access to the joint venture deals and agreements entered into by the worlds leading life science companies.


This report provides details of the latest joint venture agreements announced in the pharmaceutical, biotechnology and diagnostic sectors. Fully up to date, the report provides details of joint venture agreements from 2010.


There is an increasing willingness for parties to enter joint venture deals; such deals enable both parties to benefit from the upside of a big product win, whereas traditional licensing deals forfeit upside for near term upfront, milestone and royalty payments.


Joint venture partnering allow the parties to securitize value and reduce risk, but keep a part of the potential upside should the product reach the market. Event if the licensor does not commercialize the project they can either sell those rights to the licensee partner or another partner for an amount higher than would have been achieved at an earlier stage licensing deal.


Another reason for joint venture deals is the joint origin of a project. Drug development projects often require various scientific and technological novelties that stem from different companies. If both companies contributed to the origination of the project, then both have from the beginning a stake in the project.


The report provides a detailed understanding and analysis of how and why companies enter joint venture deals.


Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases and databases do not.


This report contains a comprehensive listing of all joint venture deals announced since 2010 as recorded in the Current Agreements deals and alliances database, including financial terms where available, plus links to online copies of actual joint venture contract documents as submitted to the Securities Exchange Commission by companies and their partners.


Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.


The initial chapters of this report provide an orientation of joint venture dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an analysis of the trends in joint venture as well as a discussion on the merits of the type of deal.


Chapter 3 provides an overview of the structure of joint venture deals. The chapter includes numerous case studies to enable understanding of joint venture deals.


Chapter 4 provides a review of the leading Joint venture deals since 2010. Deals are listed by headline value. Where the deal has an agreement contract published at the SEC a link provides online access to the contract via the Current Agreements deals and alliances database.


Chapter 5 provides a comprehensive listing of the top 50 most active Joint venture dealmaker companies. Each deal title links via Current Agreements deals and alliances database to an online version of the full deal record, and where available, the actual contract document, providing easy access to each deal record on demand.


Chapter 6 provides a comprehensive and detailed review of Joint venture deals organized by company A-Z, therapy, technology and industry type signed and announced since 2010 where a contract document is available. Contract documents provide an indepth insight into the actual deal terms agreed between the parties with respect to the Joint venture deal.


The appendices to the report includes a comprehensive listing of all Joint venture deals announced since 2010. Each listing is organized as an appendix by company A-Z, stage of development at signing, therapeutic area and industry type. Each deal title links via hyperlink to an online version of the deal record including, where available, the actual contract document.


The report also includes numerous table and figures that illustrate the trends and activities in Joint venture dealmaking since 2010.


In conclusion, this report provides everything a prospective dealmaker needs to know about Joint venture alliances.


Key benefits


Global Joint Venture Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2010-2017 provides the reader with the following key benefits:


In-depth understanding of joint venture partnering deal trends since 2010

Analysis of the structure of joint venture agreements with numerous real life case studies

Comprehensive listing of all joint venture deals since 2010, together with deal terms, value and press release

Comprehensive access to actual joint venture contracts entered into by the world’s life science companies

Insight into the terms included in a joint venture agreement, together with real world clause examples

Understand the key deal terms companies have agreed in previous deals

Undertake due diligence to assess suitability of your proposed deal terms for partner companies


Report scope


Global Joint Venture Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2010-2017 is intended to provide the reader with an in-depth understanding of the joint venture trends and structure of deals entered into by leading life science companies worldwide.


Global Joint Venture Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2010-2017 includes:


Trends in joint venture dealmaking in the biopharma industry since 2010

Analysis of joint venture deal structure

Case studies of real-life joint venture deals

Comprehensive listing of joint venture deals since 2010

Access to joint venture contract documents

The leading joint venture deals by value since 2010

Most active joint venture dealmakers since 2010

The leading joint venture partnering resources


In Global Joint Venture Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2010-2017 available deals and contracts are listed by:


Company A-Z

Headline value

Therapeutic area

Technology type


Each deal title links via Weblink to an online version of the actual deal record and where available, contract document, providing easy access to each contract document on demand.


The Global Joint Venture Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2010-2017 report provides comprehensive access to available contract documents for joint venture deals. Analyzing actual contract agreements allows assessment of the following:


What are the precise rights granted or optioned?

What is actually granted by the agreement to the partner company?

What exclusivity is granted?

What is the payment structure for the deal?

How do milestone align with clinical stage development phases?

How are salesand payments audited?

What is the deal term?

How are the key terms of the agreement defined?

How are IPRs handled and owned?

Who is responsible for commercialization?

Who is responsible for development, supply, and manufacture?

How is confidentiality and publication managed?

How are disputes to be resolved?

Under what conditions can the deal be terminated?

What happens when there is a change of ownership?

What sublicensing and subcontracting provisions have been agreed?

Which boilerplate clauses does the company insist upon?

Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?

Which jurisdiction does the company insist upon for agreement law?

Table of Contents
for Global Joint Venture Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2010-2017 [Report Updated: 01-09-2017]

  • Executive Summary

    Chapter 1 – Introduction

    Chapter 2 – Trends in joint venture partnerships

    2.1. Introduction

    2.2. Definition of joint venture deals

    2.3. Success factors for joint venture partnerships

    2.4. When joint venture partnerships can be useful

    2.5. Attributes of joint venture partnerships

    2.6. Aligning partners to make the joint venture work

    2.7. Trends in joint venture partnerships since 2010

    2.7.1. Joint venture dealmaking by year, 2010 to 2017

    2.7.2. Joint venture dealmaking by stage of development 2010 to 2017

    2.7.3. Joint venture dealmaking by industry sector 2010 to 2017

    2.7.4. Joint venture dealmaking by therapy area, 2010 to 2017

    2.7.5. Joint venture dealmaking by technology type, 2010 to 2017

    2.7.6. Joint venture dealmaking by most active company, 2010 to 2017

    2.8. The future of joint venture partnerships

    Chapter 3 – Overview of joint venture deal structure

    3.1. Introduction

    3.2. Joint venture agreement structure

    3.3. Example joint venture agreements

    3.3.1. Case study 1: Agila Specialties - Pfenex

    3.3.2. Case study 2: Dance Biopharm – Harmony Asset

    Chapter 4 – Leading joint venture deals

    4.1. Introduction

    4.2. Top joint venture deals by value

    Chapter 5 - Top 50 most active active joint venture dealmakers

    5.1. Introduction

    5.2. Top 50 most active joint venture dealmakers

    Chapter 6 – Joint venture deals including contracts directory

    6.1. Introduction

    6.2. Joint venture deals with contracts 2010 to 2017

    Appendices

    Appendix 1 – Joint venture dealmaking by companies A-Z

    Appendix 2 – Joint venture dealmaking by industry sector

    Appendix 3 – Joint venture dealmaking by stage of development

    Appendix 4 – Joint venture dealmaking by therapy area

    Appendix 5 – Joint venture dealmaking by technology type

    Appendix 6 – Joint venture references

    Appendix 7 – Resources

    Appendix 8 – Deal type definitions

    About Wildwood Ventures

    Current Partnering

    Current Agreements

    Recent report titles from CurrentPartnering

    TABLE OF FIGURES

    Figure 1: Definition of joint venture

    Figure 2: Situations where joint venture partnerships can prove useful

    Figure 3: Key components of a joint venture partnership

    Figure 4: Issues in implementing joint venture partnership agreements

    Figure 5: Trends in joint venture deal announcements, 2010- 2017

    Figure 6: Joint venture deals signed at each phase of development, 2010- 2017

    Figure 7: Joint venture deals by industry sector, 2010 to 2017

    Figure 8: Joint venture deals by therapy area, 2010 to 2017

    Figure 9: Joint venture deals by technology type, 2010 to 2017

    Figure 10: Top 50 most active joint venture dealmakers, 2010 to 2017

    Figure 11: Joint venture shareholder agreements – what should a contract include?

    Figure 12: Components of the joint venture deal structure

    Figure 13: Top joint venture deals by value since 2010

    Figure 14: Most active joint venture dealmakers 2010 to 2017

    Figure 15: Online partnering resources

    Figure 16: Deal type definitions

Additional Details

Publisher

Current Partnering

Publisher Information

Reference

117451 | CP2060

Number of Pages

439

Report Format

PDF

Current Partnering Reports

Related Reports

TitleDate PublishedPrice fromMore Details
OPC Pharmaceutical Joint Stock Company (OPC) - Financial and Strategic SWOT Analysis Review
SummaryOPC Pharmaceutical Joint Stock Company (OPC Pharmaceutical) is a pharmaceutical company that ...
11 Jul 2016 by Global Data USD $300 More Info
Traphaco Joint Stock Company (TRA) - Financial and Strategic SWOT Analysis Review
SummaryTraphaco Joint Stock Company (Traphaco) is a pharmaceutical company that manufactures and tra...
11 Jul 2016 by Global Data USD $300 More Info
OPC Pharmaceutical Joint Stock Company (OPC) - Financial and Strategic SWOT Analysis Review
SummaryOPC Pharmaceutical Joint Stock Company (OPC Pharmaceutical) is a pharmaceutical company that ...
15 Apr 2016 by Global Data USD $300 More Info
Traphaco Joint Stock Company (TRA) - Financial and Strategic SWOT Analysis Review
SummaryTraphaco Joint Stock Company (Traphaco) is a pharmaceutical company that manufactures and tra...
15 Apr 2016 by Global Data USD $300 More Info
OPC Pharmaceutical Joint Stock Company (OPC) - Financial and Strategic SWOT Analysis Review
SummaryOPC Pharmaceutical Joint Stock Company (OPC Pharmaceutical) is a pharmaceutical company that ...
09 Jan 2016 by Global Data USD $300 More Info
Traphaco Joint Stock Company (TRA) - Financial and Strategic SWOT Analysis Review
SummaryTraphaco Joint Stock Company (Traphaco) is a pharmaceutical company that manufactures and tra...
09 Jan 2016 by Global Data USD $300 More Info
Prosthetic joint infections Global Clinical Trials Review, H2, 2015
Prosthetic joint infections Global Clinical Trials Review, H2, 2015SummaryGlobalData's clinical tria...
25 Nov 2015 by Global Data USD $2,500 More Info
OPC Pharmaceutical Joint Stock Company (OPC) - Financial and Strategic SWOT Analysis Review
SummaryOPC Pharmaceutical Joint Stock Company (OPC Pharmaceutical) is a pharmaceutical company that ...
08 Nov 2015 by Global Data USD $300 More Info
Traphaco Joint Stock Company (TRA) - Financial and Strategic SWOT Analysis Review
SummaryTraphaco Joint Stock Company (Traphaco) is a pharmaceutical company that manufactures and tra...
08 Nov 2015 by Global Data USD $300 More Info
North American Joint Reconstruction Market by Type (Ankle Replacement, Digit Replacement, Elbow Replacement, Hip Replacement, Knee Replacement, Shoulder Replacement) - Forecast to 2019
The North American joint reconstruction market is estimated to grow at a CAGR of 5.1% from 2014 to 2...
08 Apr 2015 by MicroMarketMonitor USD $2,650 More Info

This report is published by Current Partnering

Download Free Report Summary PDF

Global Joint Venture Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2010-2017 [Report Updated: 01-09-2017] | Download PDF Summary

Download our FREE report summary PDF. It contains all the information on these web pages, plus a Proforma Invoice request form, should you need it to satisfy your company's internal order procedures.

Ordering Information

Orders are processed immediately and you will be notified of the despatch date on confirmation of your order.

Accepted Card Types

Payment

Buy now using our secure payment system.

We Stock...

  • Allied Market Research
  • CBR Pharma
  • Current Partnering
  • Firstword
  • Global Data
  • Global Markets Direct
  • ICD Research
  • Infinti Research Technavio
  • Marketline
  • Markets and Markets
  • Micro Markets Monitor
  • MP Advisors
  • Venture Planning Group
  • GMR Data